Anzeige
Mehr »
Donnerstag, 17.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 | ISIN: US09058V1035 | Ticker-Symbol: BO1
Tradegate
16.07.25 | 18:55
7,446 Euro
+0,92 % +0,068
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,3347,48209:38
7,3347,48209:39

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaRBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $135
07.07.BioCryst Pharma Appoints Babar Ghias As CFO-
07.07.BioCryst appoints Babar Ghias as CFO1
07.07.BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development441RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head...
► Artikel lesen
07.07.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report1
03.07.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)115RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted...
► Artikel lesen
01.07.IN BRIEF: BioPharma Credit to be repaid following disposal by BioCryst5
01.07.BioPharma Credit PLC - STATEMENT RE BIOCRYST2
BIOCRYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
01.07.Neopharmed Gentili erwirbt das europäische ORLADEYO®-Geschäft von BioCryst Pharmaceuticals3
30.06.Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo2
29.06.BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal5
27.06.Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules6
27.06.BioCryst Just Ditched Its Europe Business - Here's Why Investors Are Cheering2
27.06.BioCryst-Aktie steigt nach Verkauf des europäischen ORLADEYO-Geschäfts für 264 Millionen US-Dollar4
27.06.BioCryst stock rises after $264 million sale of European ORLADEYO business2
27.06.BioCryst to sell European Orladeyo business for up to $264M1
27.06.BioCryst verkauft europäisches ORLADEYO-Geschäft an Neopharmed für 264 Mio. US-Dollar2
27.06.BioCryst to sell European ORLADEYO business to Neopharmed for $264M3
27.06.BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million727-Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones- -BioCryst plans to use proceeds to...
► Artikel lesen
25.06.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report2
Weiter >>
94 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1